A Randomized, Double-Blind, Within-Subject Placebo Controlled Study to Evaluate the Safety and Efficacy of Various Doses of STP705 Administered as Intradermal Injection in Subjects With Hypertrophic Scar

Trial Profile

A Randomized, Double-Blind, Within-Subject Placebo Controlled Study to Evaluate the Safety and Efficacy of Various Doses of STP705 Administered as Intradermal Injection in Subjects With Hypertrophic Scar

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Dec 2017

At a glance

  • Drugs STP 705 (Primary)
  • Indications Hypertrophic scars
  • Focus First in man; Therapeutic Use
  • Sponsors Sirnaomics
  • Most Recent Events

    • 06 Feb 2017 Status changed from not yet recruiting to recruiting, according to Sirnaomics media release.
    • 11 Nov 2016 Status changed from planning to not yet recruiting.
    • 07 Nov 2016 According to Sirnaomics media release, IND application for the Phase IIa clinical study, has received an approval from U.S. Food and Drug Administration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top